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Background
Monocarboxylate transporters (MCTs) are transmem-
brane proteins that facilitate the transport of important
monocarboxylates such as lactate across the cell mem-
brane. Thus, these transporters play a central role in
tumour metabolism and, as a result, are attractive tar-
gets in cancer therapy, which are now starting to be
explored in the clinical context.
Materials and methods
Expression of key metabolic markers was assessed by
immunohistochemistry in 480 prostate samples and pros-
tate cell lines. The levels of glycolytic metabolism were
assessed using commercial colorimetric assays. The effect
of the MCT inhibitor and thioridazine was evaluated on
cell viability by using the Sulforhodamine B assay. Finally,
ultra-structural studies were performed by classical elec-
tron microscopy transmission techniques.
Results
Firstly, we observed an overexpression of proteins involved
in oxidative phosphorylation and lipidic b-oxidation in
localized prostate cancer, which expression was already
evident in precursor lesions. Importantly, only proteins
involved in glycolytic metabolism were associated with
poor prognosis and the same proteins, despite expressed
at low levels in localized tumour, were highly expressed in
the metastatic samples. Secondly, prostate cancer cell lines
showed important differences at metabolic and ultrastruc-
tural levels. The less aggressive LNCaP cells exhibited a
more oxidative phenotype whereas the highly aggressive
and metastatic cell lines PC3 and DU145 were more glyco-
lytic. Finally, the distant metastatic prostate cancer cell
lines were more sensitive to CHC (MCT inhibitor) than
LNCaP cells.
Conclusions
These studies demonstrate differences in the metabolism
of prostate cancer cells, which could be relevant on the
development of new diagnostic, prognostic and therapeu-
tic strategies involving metabolic targets.
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